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INTRODUCTION
Medical screening is the search in a population for individu-
als with a given disease or the search for individuals at incre-
ased risk for this disease. Although screening is an epidemio-
logical term, in preventive medicine it is understood as an
action aimed at early diagnosis of a disease at a stage without
signs or symptoms. In this form, medical screening, also cal-
led case-finding, is a strategy to identify ill patients unaware
of their status and to offer them early treatment.
Two major screening strategies are applicable. The first is
mass screening, involving whole populations on a large scale
without any prior selection. The second strategy is called se-
lective screening. This can be conducted on a large scale, but
it is usually limited to selected groups in the population who
are at high risk of having a particular disease. Screening is
usually implemented as an application of a certain test or
examination. When combined with a structured interview
(history taking) or physical examination, it is often called ‘ear-
ly disease detection’. Opportunistic screening is the selective
application of screening procedures (at the discretion of he-
althcare workers) to users of the healthcare system. For exam-
ple, patients who visit their family doctor’s surgery for any
reason may be offered a screening procedure.
The expected benefits of screening are based on the as-
sumption that early diagnosis can lead to early treatment, re-
sulting in a better prognosis. This might be true. However, in
particular cases, screening can cause significant harm related
to false positive findings, unnecessary treatment of potential-
ly innocent conditions, side effects of the diagnostic and cu-
rative procedures, and wasted expenditure. Certain screening
techniques, although very effective, are unacceptable for pa-
tients due to their invasive nature or other inconvenience.
Other procedures may involve high costs, unacceptable for
individuals or societies. To balance the advantages and dis-
advantages of screening, the World Health Organisation has
developed recommendations for good practice in this field,
which are still widely applicable [1].
Cardiovascular (CV) diseases remain a major public he-
alth problem in most European countries, including Poland.
They are still the main cause of mortality and strongly influ-
ence quality of life, predominantly through their impact on
disability [2]. The value of preventive measures has been well
documented for all kinds of interventions, including lifestyle
modifications and drug treatment. There is evidence that be-
nefits related to the long-term presence of a low risk status
are particularly significant. Thus a strategy aimed at the early
identification and elimination of several risk factors is espe-
cially effective [3]. There is no doubt that community based
preventive programmes can reduce overall CV risk and are
important tools for the improvement of public health [4]. These
strategies, if adequately designed and financed, have proved
their cost effectiveness [5].
These guidelines are based on the best existing evidence
and international experience [6]. However, they also take into
consideration specifics of the Polish healthcare system and
epidemiology as well as the need for coherence with the pre-
vious recommendations of the Polish Forum for Prevention of
Cardiovascular Diseases [7]. They remain an important tool
helping nurses, physicians, policy makers and decision makers
to decrease the burden of CV diseases in Poland.
1312
www.kardiologiapolska.pl
Adam Windak et al.
GUIDELINES
I. Screening for any disease is justified only when all the
following conditions are met [1]:
1. The disease should significantly influence life expec-
tancy or quality of life.
2. Acceptable treatment methods should be available.
3. The disease should have an asymptomatic period, and
early diagnosis significantly reduces morbidity and
mortality.
4. Treatment in the asymptomatic period gives better
results than treatment started when symptoms and
signs are present.
5. Acceptable and affordable tests to diagnose a disease
in an asymptomatic stage are available.
6. Morbidity has to be high enough to justify the costs of
screening.
II. Blood pressure should be measured in all individuals over
the age of 3 at least once a year; but in children with
blood pressure between the 90th and 95th percentiles, as
well as adults with previous readings falling in the range
120–139/80–89 mm Hg, blood pressure should be me-
asured more often [8–10].
III. Healthy adults aged 20 years or older should be measu-
red for total cholesterol level at least once every 5 years.
The full lipid profile should be measured in all patients
with high CV risk. Blood lipids should be measured also
in children older than 2 years with a family history of
dyslipidaemia, including family hypercholesterolaemia or
the early onset of CV diseases, as well as in children with
other risk factors, including those with an uncertain fa-
mily history [9, 11, 12]*.
IV. All patients older than 45 years should be screened for
type 2 diabetes mellitus. In cases of impaired fasting glu-
cose, an oral glucose tolerance test should be performed.
In all high risk patients and in those with pre-diabetes,
the measurements should be repeated every 1–2 years,
irrespective of age [9, 13].
V. In all patients older than 10 years, smoking status should
be assessed. A minimal intervention to quit smoking sho-
uld be offered to all smokers, according to the ‘5A stra-
tegy’ (the 5As are: Ask, Assess, Advise, Assist, Arrange)
[14–16].
VI. In all visibly overweight patients, body mass index (BMI)
and waist circumference should be measured every
2 years. For overweight (BMI > 25 kg/m2) and obese
(BMI > 30 kg/m2) patients and those with abdominal
obesity, individual education about lifestyle changes and
skills training should be offered [17, 18].
VII. All patients older than 13 years should be asked about
the amount and frequency of their alcohol drinking as
well as the number of days per week without alcohol
consumption. All risky drinkers (threatening themselves
or others) should be offered a short intervention to limit
alcohol drinking [19, 20].
VIII. All smokers aged 55 years or older, with hypertension,
type 2 diabetes mellitus or multiple CV risk factors sho-
uld be asked once a year about the presence of any signs
or symptoms suggesting transient ischaemic attacks
[9, 21].
IX. Urinalysis should be performed once a year in all pa-
tients older than 55 years. In patients with high risk of
renal diseases (i.e. diagnosed CV disease, type 2 diabe-
tes mellitus, hypertension, or a family history of chronic
renal disease) estimated glomerular filtration rate (eGFR)
should be measured according to the short MDRD for-
mula [22–24]: eGFR = 186 × [Pcr : 88.4]
–1.154 × age–0.203
[mL/min/1.73 m2 body surface]; in women, the result
must be multiplied by 0.742; in black people, the result
must be multiplied by 1.21 (Pcr — creatinine serum level
in mg/dL; age in years).
X. Screening should be organised, conducted and co-ordi-
nated within separately financed preventive programmes.
These programmes should include an interventional com-
ponent, focused on modification of identified risk fac-
tors. Adequate public resources should be allocated to
these programmes [4].
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